[go: up one dir, main page]

HK1045646A1 - Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof - Google Patents

Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Info

Publication number
HK1045646A1
HK1045646A1 HK02105870.2A HK02105870A HK1045646A1 HK 1045646 A1 HK1045646 A1 HK 1045646A1 HK 02105870 A HK02105870 A HK 02105870A HK 1045646 A1 HK1045646 A1 HK 1045646A1
Authority
HK
Hong Kong
Prior art keywords
methods
preparation
active agents
pharmacologically active
protein stabilized
Prior art date
Application number
HK02105870.2A
Other languages
Chinese (zh)
Inventor
P Desai Neil
Tao Chunlin
Yang Andrew
Louie Leslie
Yao Zhiwen
Soon-Shiong Patrick
Magdassi Shlomo
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/316,642 external-priority patent/US6749868B1/en
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of HK1045646A1 publication Critical patent/HK1045646A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK02105870.2A 1999-05-21 2002-08-12 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof HK1045646A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/316,642 US6749868B1 (en) 1993-02-22 1999-05-21 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PCT/US2000/013954 WO2000071079A2 (en) 1999-05-21 2000-05-19 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Publications (1)

Publication Number Publication Date
HK1045646A1 true HK1045646A1 (en) 2002-12-06

Family

ID=23229970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02105870.2A HK1045646A1 (en) 1999-05-21 2002-08-12 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Country Status (5)

Country Link
EP (1) EP1178786A4 (en)
AU (3) AU784416B2 (en)
CA (2) CA2371912C (en)
HK (1) HK1045646A1 (en)
WO (1) WO2000071079A2 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
MXPA02004164A (en) * 1999-10-27 2002-10-17 Baker Norton Pharma Method and compositions for administering taxanes orally to human patients.
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
JP2005504090A (en) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド Preparation of submicron size-nanoparticles by removal of dispersion and solvent or liquid phase
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
EP1478343B1 (en) * 2001-10-15 2017-03-22 Crititech, Inc. Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
ITMI20020680A1 (en) * 2002-03-29 2003-09-29 Acs Dobfar Spa IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING
NZ518997A (en) * 2002-05-16 2004-12-24 Interag Injection formulation for parenteral administration of biodegradable implant for sustained release of active agent
SI21222A (en) * 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Method for preparation of nanoparticles
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
ES2685436T3 (en) 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Compositions and procedures for administration of pharmacological agents
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
WO2006073154A1 (en) * 2005-01-07 2006-07-13 Eisai R&D Management Co., Ltd. Medicinal composition and process for producing the same
CN103169729A (en) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 Methods and compositions for treating proliferative diseases
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX2007015183A (en) * 2005-06-14 2008-02-19 Baxter Int Pharmaceutical formulations for minimizing drug-drug interactions.
RU2433818C2 (en) 2005-08-31 2011-11-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Compositions, including poorly soluble in water pharmaceutic substances and antimicrobial substances
WO2007069272A2 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
JP5301995B2 (en) * 2006-08-29 2013-09-25 富士フイルム株式会社 Hydrophilic matrix encapsulating poorly water-soluble compounds and process
WO2008076373A1 (en) 2006-12-14 2008-06-26 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
MX380318B (en) 2007-03-07 2025-03-12 Abraxis Bioscience Llc NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS AN ANTI-CANCER AGENT.
PT2155188E (en) 2007-06-01 2013-12-19 Abraxis Bioscience Llc Methods and compositions for treating recurrent cancer
FR2924024B1 (en) * 2007-11-27 2012-08-17 Centre Nat Rech Scient NANOPARTICLES OF THERAPEUTIC ACTIVE INGREDIENTS OF LOW AQUEOUS SOLUBILITY
KR20100048751A (en) * 2008-10-31 2010-05-11 주식회사 동성바이오레인 Capsulated functional dual core aerosol composition and the method for their manufacture
AU2009319183B2 (en) 2008-11-27 2014-06-05 B.R.A.I.N. Biotechnology Research And Information Network Ag Hydrophobins as surface active proteins as excipients in solid pharmaceutical formulations
KR101722961B1 (en) 2009-02-11 2017-04-04 알부메딕스 에이/에스 Albumin variants and conjugates
KR20120044279A (en) 2009-04-15 2012-05-07 아브락시스 바이오사이언스, 엘엘씨 Prion-free nanoparticle compositions and methods
US8748380B2 (en) 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
CA2793536C (en) 2010-03-26 2019-10-01 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
MX369728B (en) 2010-03-29 2019-11-20 Abraxis Bioscience Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents.
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
KR20190130050A (en) 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 Methods of treatment of pancreatic cancer
SMT201900502T1 (en) 2011-12-14 2019-11-13 Abraxis Bioscience Llc Use of polymeric excipients for lyophilization or freezing of particles
US9944691B2 (en) 2012-03-16 2018-04-17 Albumedix A/S Albumin variants
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
PT106738B (en) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa METHOD FOR THE CONTROL OF OSTWALD DIFUSIONAL DEGRADATION PHENOMENON (OSTWALD RIPENING) IN THE PROCESSING OF PARTICLES OF A PHARMACEUTICAL INGREDIENT
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CN105007722A (en) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 Pharmacokinetic animal model
CN110279864A (en) 2013-03-12 2019-09-27 阿布拉科斯生物科学有限公司 The method for treating lung cancer
MX378934B (en) 2013-03-14 2025-03-11 Abraxis Bioscience Llc Methods of treating bladder cancer
CN104548116A (en) * 2013-10-11 2015-04-29 程树海 Preparation method of stable protein drug-loaded microparticle system
WO2015018380A2 (en) 2014-07-03 2015-02-12 Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. Therapeutic nanoparticles and the preparation methods thereof
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
EA036790B1 (en) 2015-06-29 2020-12-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Method of treating malignant pecoma
MX2018001825A (en) 2015-08-20 2018-05-07 Albumedix As Albumin variants and conjugates.
CN110337590A (en) 2016-11-04 2019-10-15 奥胡斯大学 Identification and treatment of tumors characterized by neonatal Fc receptor overexpression
DE102016125666A1 (en) * 2016-12-23 2018-06-28 Michael Denck HSA Galenik
CN110753541A (en) * 2017-04-24 2020-02-04 Zy治疗公司 Pharmaceutical compositions for in vivo delivery, process for preparing substantially water insoluble pharmacologically active agents
CA3094453A1 (en) 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
BR112022007710A2 (en) 2019-10-28 2022-07-12 Abraxis Bioscience Llc PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMICIN
US20230025865A1 (en) * 2019-12-11 2023-01-26 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CN100462066C (en) * 1997-06-27 2009-02-18 美国生物科学有限公司 Novel formulations of pharmacological agents, method for preparation thereof and method for use thereof

Also Published As

Publication number Publication date
AU2006202836B2 (en) 2009-10-08
EP1178786A4 (en) 2006-03-01
WO2000071079A2 (en) 2000-11-30
AU2006202836A1 (en) 2006-07-27
EP1178786A1 (en) 2002-02-13
AU784416B2 (en) 2006-03-30
CA2684454A1 (en) 2000-11-18
CA2371912A1 (en) 2000-11-30
AU2009217409A1 (en) 2009-10-08
AU5035900A (en) 2000-12-12
CA2371912C (en) 2010-02-16
WO2000071079A3 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
HK1045646A1 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
HK1050367A1 (en) Pharmaceutically active compounds.
AP2000001869A0 (en) Pharmaceutically active morpholinol
HK1048999A1 (en) Azepinoindole derivatives, their preparation and use thereof
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
HK1054386A1 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
HK1048306A1 (en) Pharmaceutically active sulfonamide derivatives.
IL150022A0 (en) Imidazo [1,3,5] triazinones and the use thereof
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
HK1040398A1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
HUP0105039A3 (en) Fungicidal propargylether derivatives, preparation and use thereof
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
HK1031725A1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
AU2662799A (en) Modified pharmacologically active agents and improved therapeutic methods employing same
HUP0202377A2 (en) N-substituted perhydrodiazines, preparation and use thereof
ZA200110046B (en) Therapeutic agents.
EP1234834A4 (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
SI1043306T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and use
ZA989312B (en) Novel pharmaceutically active compounds, their preparation and use.
HUP0203678A3 (en) Nitro-sulfobenzamide-derivatives, preparation and use thereof
HUP0203455A3 (en) 2-arylquinoline derivatives, preparation and therautic use thereof
IL150237A0 (en) Benzophenone glycopyranosides, preparation and therapeutic use
AUPP899699A0 (en) Peptides, agents and methods
GB9801230D0 (en) Pharmaceutically active morpholinol
IL158978A0 (en) Pharmaceutically active morpholinol